Expression of the chemokine CXCL14 and cetuximab-dependent tumour suppression in head and neck squamous cell carcinoma.

Research Project

Project/Area Number	15K11277
Research Category	Grant-in-Aid for Scientific Research (C)
Allocation Type	Multi-year Fund
Section	一般
Research Field	Surgical dentistry
Research Institution	Kanagawa Dental College
Principal Investigator	KONDO Tadanori 神奈川歯科大学, 歯学部, 非常勤講師 (00587727)
Co-Investigator(Kenkyū-buntansha)	小澤重幸神奈川歯科大学, 大学院歯学研究科, 講師 (40434394) 宮本千央神奈川歯科大学, 大学院歯学研究科, 特任講師 (50633963)
Project Period (FY)	2015-04-01 – 2018-03-31
Project Status	Completed (Fiscal Year 2017)
Budget Amount *help	¥4,810,000 (Direct Cost: ¥3,700,000、Indirect Cost: ¥1,110,000) Fiscal Year 2017: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000) Fiscal Year 2016: ¥1,300,000 (Direct Cost: ¥1,000,000、Indirect Cost: ¥300,000) Fiscal Year 2015: ¥1,950,000 (Direct Cost: ¥1,500,000、Indirect Cost: ¥450,000)
Keywords	CXCL14 / 異常メチル化 / 頭頚部扁平上皮癌 / セツキシマブ / メチル化異常 / メチル化 / 頭頸部扁平上皮癌 / ケモカイン / エピジェネチック異常
Outline of Final Research Achievements	The present study aimed to prove the relationship between aberrant methylation and cetuximab resistance based on the hypothesis that aberrant methylation is a factor involved as a cause of cetuximab resistance in addition to the aforementioned genetic mutations. For this study, we originally planned to conduct investigations using biopsy samples of patients administered cetuximab, but unexpectedly, we were unable to obtain any of the said biopsy samples. Instead we proved the relationship between cetuximab resistance and methylation by increasing the group using cell lines. Cells with aberrant methylation exhibited cetuximab resistance in HSC-3 as well as other cell lines.